|
|||||
|
|
A phase I clinical trial demonstrates that nfP2X7‐targeted antibodies provide a novel,safe and tolerable topical therapy for basal cell carcinoma |
|
| Authors: | S.M. Gilbert A. Gidley Baird S. Glazer J.A. Barden A. Glazer L.C. Teh J. King |
| Affiliation: | 1. Babraham Research Campus, Biosceptre (U.K.) Limited, Cambridge, U.K;2. Correspondence;3. Simon Gilbert.;4. E‐mail:;5. Biosceptre (Australia) Pty Ltd., 11 Julius Avenue, North Ryde, NSW, 2113 Australia;6. Glazer Dermatology, Buffalo Grove, IL, U.S.A |
| Abstract: | |
| Keywords: | |